Use of Bevacizumab in the Maintenance Setting for Patients with Metastatic Colorectal Cancer (mCRC)

CME test	Downloadable PDF	PowerPoint slides	CME Information and Faculty Disclosures
Read Dr Love's original email (from August 3, 2010)			Subscribe to Dr Love's email alerts

Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Richard M Goldberg, MD (6/23/10), Axel Grothey, MD (7/9/10) and Alan P Venook, MD (6/16/10)

 

Tabernero J et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent BEV as maintenance therapy in patients with metastatic colorectal cancer: The MACRO trial. Proc ASCO 2010;Abstract 3501.

Go to previous Journal Club